Julian Baker Baker Bros. Advisors
Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rhythm Pharmaceuticals
RYTM
|
+$36M |
| 2 |
AKRO
Akero Therapeutics
AKRO
|
+$34.4M |
| 3 |
Veru
VERU
|
+$23.2M |
| 4 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
+$22.8M |
| 5 |
IDEAYA Biosciences
IDYA
|
+$21.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$311M |
| 2 |
Insmed
INSM
|
+$51.2M |
| 3 |
Legend Biotech
LEGN
|
+$47.1M |
| 4 |
Krystal Biotech
KRYS
|
+$27.9M |
| 5 |
Pacific Biosciences
PACB
|
+$24.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.7% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Nurix Therapeutics
NRIX
$2.77B
| $50.6M | 0.33% |
3,882,125
| – | – |
|
|
KDNY
27
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $49.8M | 0.33% |
2,534,102
| – | – |
|
|
VERV
28
DELISTED
Verve Therapeutics
VERV
| $48.7M | 0.32% |
1,416,530
| – | – |
|
29
Immatics
IMTX
$1.22B
| $44.2M | 0.29% |
4,423,731
| – | – |
|
|
FMTX
30
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $37.6M | 0.25% |
1,886,760
-138,116
| -7% | -$1.82M |
|
31
Kiniksa Pharmaceuticals
KNSA
$6.17B
| $35.9M | 0.24% |
2,799,577
| – | – |
|
32
Heron Therapeutics
HRTX
$60.4M
| $34.3M | 0.22% |
8,131,678
| – | – |
|
|
JBIO
33
Jade Biosciences
JBIO
$1.36B
| $32.8M | 0.21% |
56,559
-2,584
| -4% | -$1.73M |
|
|
TSVT
34
DELISTED
2seventy bio
TSVT
| $30M | 0.2% |
2,062,744
| – | – |
|
|
35
Krystal Biotech
KRYS
$10.3B
| $29.4M | 0.19% |
422,185
-385,550
| -48% | -$27.9M |
|
36
Xenon Pharmaceuticals
XENE
$5.88B
| $27.1M | 0.18% |
751,639
| – | – |
|
|
CINC
37
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $26.5M | 0.17% |
+807,212
| New | +$22.8M |
|
|
DBVT
38
DBV Technologies
DBVT
$914M
| $25.9M | 0.17% |
1,461,426
| – | – |
|
|
39
IDEAYA Biosciences
IDYA
$3.83B
| $24.9M | 0.16% |
+1,668,355
| New | +$21.7M |
|
40
Design Therapeutics
DSGN
$938M
| $24M | 0.16% |
1,436,636
| – | – |
|
41
Verastem
VSTM
$624M
| $22.9M | 0.15% |
2,249,075
| – | – |
|
42
Altimmune
ALT
$605M
| $22.6M | 0.15% |
1,769,681
-305,722
| -15% | -$4.51M |
|
|
NVTA
43
DELISTED
Invitae Corporation
NVTA
| $20.7M | 0.14% |
8,402,035
-1,471,453
| -15% | -$4.47M |
|
44
Biomea Fusion
BMEA
$99.3M
| $20.6M | 0.13% |
2,104,559
| – | – |
|
|
BCYC
45
Bicycle Therapeutics
BCYC
$306M
| $19.6M | 0.13% |
+843,814
| New | +$20.1M |
|
46
Ultragenyx Pharmaceutical
RARE
$2.55B
| $19.5M | 0.13% |
470,974
| – | – |
|
47
Instil Bio
TIL
$51.4M
| $18.8M | 0.12% |
194,685
| – | – |
|
|
48
Veru
VERU
$45M
| $18.5M | 0.12% |
+160,958
| New | +$23.2M |
|
49
Relmada Therapeutics
RLMD
$494M
| $18.3M | 0.12% |
495,113
| – | – |
|
50
Alkermes
ALKS
$8.11B
| $18.2M | 0.12% |
815,016
-684,984
| -46% | -$17.8M |
|
Similar funds
Julian Baker's Q3 2022 Portfolio in Review
As of Q3 2022, Julian Baker held 128 positions worth $15.3B, down 13% from $17.6B the previous quarter. Its ten largest holdings account for 85% of the portfolio.
Julian Baker's Q3 2022 filing shows 12 new, 7 increased, 17 reduced and 13 closed positions. Its largest new stake was Veru: 160,958 shares worth $18.5M. The largest sale was argenx, an estimated $311M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.
- Julian Baker's largest Q3 2022 buy was Veru: 160,958 shares worth $18.5M.
- Julian Baker added most to Rhythm Pharmaceuticals in Q3 2022, an estimated $36M increase.
- Julian Baker's biggest Q3 2022 reduction was argenx, cutting an estimated $311M.
- Julian Baker fully exited Legend Biotech in Q3 2022, selling an estimated $47.1M.
- Julian Baker's ten largest holdings make up 85% of its $15.3B portfolio in Q3 2022.
- Julian Baker opened 12 new positions and closed 13 in Q3 2022.
- Julian Baker's portfolio value fell 13% quarter-over-quarter to $15.3B.
Based on Baker Bros. Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.